Metabolic dysfunction-associated steatohepatitis (MASH) is conventionally investigated and treated as a primary disease of the liver. In type 2 diabetes, however, the hepatic lesion is best understood as the visible endpoint of a systemic disorder of adipose tissue. This review develops the mechanistic case for that re...
S. Corrao, C. Argano· Frontiers in Endocrinology· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver condition worldwide, reflecting the growing global burden of obesity and type 2 diabetes (T2D). The complex pathophysiology of MASLD, characterized by insulin resistance (IR), lipotoxicity, and chronic low-g...
C. Argano, Dalila Maggio, Chiara Pollicino et al.· Frontiers in Pharmacology· 0 citations
Abdominal adiposity identifies steatosis risk in a graded manner but does not discriminate fibrosis, supporting adiposity- and sex-informed hepatic phenotyping in patients with T2DM.
S. Corrao, S. Scibetta, Brenda Bongiorno et al.· Acta Diabetologica· 0 citations
This Commentary proposes that repeated, methodologically guided dialogue with personalised large language models-termed Clinical Cognitive Interaction-progressively imprints the physician's epistemic signature onto a personalised exocortex, giving rise to an emergent Human-LLM Cognitive Unit.
S. Corrao· QJM : monthly journal of the...· 0 citations
Cognitive safety is proposed here as a longitudinal property of the clinician-AI-organization sociotechnical system: its capacity to support or improve clinical performance without eroding independent hypothesis generation, uncertainty calibration, reasoned dissent, metacognitive control, and resilient performance when...
S. Corrao· Recenti progressi in medicin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.